Takeda recommends common-sense policy reforms designed to reduce time to diagnosis, improve access to care for patients with rare disease

Cambridge, mass.--(business wire)--as part of its commitment to reducing burdens facing the rare disease community, takeda pharmaceutical company limited (tse:4502/nyse:tak) (“takeda”) today announced three priority policy reforms and solutions designed to address significant barriers to care for patients managing rare diseases and genetic conditions as part of a new report, “reducing time to diagnosis for people living with rare diseases: a conversation on u.s. policy opportunities.” the propo
TAK Ratings Summary
TAK Quant Ranking